-$0.56 EPS Expected for Wave Life Sciences Ltd. (NASDAQ:WVE) This Quarter

Analysts forecast that Wave Life Sciences Ltd. (NASDAQ:WVEGet Rating) will report ($0.56) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Wave Life Sciences’ earnings. The lowest EPS estimate is ($0.64) and the highest is ($0.45). Wave Life Sciences posted earnings per share of ($0.86) in the same quarter last year, which indicates a positive year over year growth rate of 34.9%. The firm is expected to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Wave Life Sciences will report full-year earnings of ($1.98) per share for the current year, with EPS estimates ranging from ($2.52) to ($1.42). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.86) per share, with EPS estimates ranging from ($2.42) to ($1.11). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVEGet Rating) last announced its quarterly earnings results on Thursday, March 3rd. The company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.14). The company had revenue of $1.77 million for the quarter, compared to the consensus estimate of $18.14 million. During the same quarter in the prior year, the firm earned ($0.59) EPS.

WVE has been the topic of a number of recent analyst reports. StockNews.com assumed coverage on shares of Wave Life Sciences in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Wave Life Sciences in a report on Friday, March 4th.

In other Wave Life Sciences news, CEO Paul Bolno sold 33,150 shares of the company’s stock in a transaction that occurred on Wednesday, February 16th. The stock was sold at an average price of $2.32, for a total transaction of $76,908.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 63,080 shares of company stock worth $146,152 in the last quarter. 28.40% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its position in Wave Life Sciences by 309.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,396 shares of the company’s stock worth $36,000 after buying an additional 5,591 shares during the last quarter. Point72 Hong Kong Ltd boosted its holdings in Wave Life Sciences by 227.6% in the third quarter. Point72 Hong Kong Ltd now owns 7,843 shares of the company’s stock worth $38,000 after purchasing an additional 5,449 shares during the last quarter. Citigroup Inc. grew its position in Wave Life Sciences by 69.7% in the 3rd quarter. Citigroup Inc. now owns 8,158 shares of the company’s stock worth $40,000 after purchasing an additional 3,352 shares during the period. Invesco Ltd. purchased a new stake in Wave Life Sciences during the 2nd quarter valued at $84,000. Finally, Barclays PLC grew its holdings in shares of Wave Life Sciences by 225.6% in the third quarter. Barclays PLC now owns 15,617 shares of the company’s stock worth $77,000 after acquiring an additional 10,821 shares during the period. 71.42% of the stock is currently owned by institutional investors.

Wave Life Sciences stock opened at $1.93 on Thursday. Wave Life Sciences has a 1-year low of $1.79 and a 1-year high of $7.55. The firm has a market capitalization of $117.43 million, a PE ratio of -0.81 and a beta of 0.52. The firm’s 50 day simple moving average is $2.28 and its 200 day simple moving average is $3.10.

Wave Life Sciences Company Profile (Get Rating)

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.

Recommended Stories

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.